SHINE

Telix and SHINE partner for Lutetium-177 Supply

Retrieved on: 
Giovedì, Febbraio 10, 2022
ASX, Patient, Australian Nuclear Science and Technology Organisation, Food, CEO, Degenerative disease, The Amazing Race Canada 4, ANSTO, Company, Australian Securities Exchange, Kidney cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ITM, Gallium, Radionuclide, LinkedIn, Twitter, TLX, MTR, FDA, SHINE, Partnership, TGA, GLOBE, LLC, Medical imaging, Pharmaceutical industry, Facebook, Telix

MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.)

Key Points: 
  • MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.)
  • SHINE will immediately commence supply of n.c.a.
  • Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
  • Its global supplier network includes a commercial supply agreement with ITM Isotope Technologies Munich SE (ITM), and clinical supply agreements with the Australian Nuclear Science and Technology Organisation (ANSTO), Eczacba-Monrol (Monrol), Eckert & Ziegler Strahlen- und Medizintechnik AG (EZAG) and SHINE Technologies.

Genuv Teams With Aiforia to Create an AI-Powered Version of its ATRIVIEW® Drug Screening Platform

Retrieved on: 
Martedì, Febbraio 15, 2022
Health, Technology, Other Technology, Clinical Trials, Pharmaceutical, Biotechnology, Amyotrophic lateral sclerosis, CNS, CEO, Biomarker, Neurodegeneration, Brain, Neuron, Neuroprotection, Efficiency, Clinical trial, Adult, Lou, Technology, Boehringer Ingelheim, ALS, AstraZeneca, Sanofi, Disorder, Artificial intelligence, Neurogenesis, Deep learning, Solubility, Marie Cassidy, SHINE, Partnership, Bristol Myers Squibb, Antibody, Homeostasis, Central nervous system, Translation, Pharmaceutical industry, Medical imaging

The new version, ATRIVIEW AI, will seamlessly incorporate Aiforias deep learning artificial intelligence technology to speed and automate image analysis within Genuvs ATRIVIEW drug discovery platform.

Key Points: 
  • The new version, ATRIVIEW AI, will seamlessly incorporate Aiforias deep learning artificial intelligence technology to speed and automate image analysis within Genuvs ATRIVIEW drug discovery platform.
  • Aiforia is helping Genuv bring the power of deep learning artificial intelligence to our unique ATRIVIEW drug discovery platform, said Sungho Han, Ph.D., founder and CEO of Genuv.
  • The ATRIVIEW drug screening platform uses cell phenotypic and biomarker analyses to discover substances for the development of neurodegenerative disease treatment.
  • ATRIVIEW AI is the next generation of ATRIVIEW, Genuvs proprietary CNS drug screening platform.

KBR Selected as Primary Provider of Space Medicine Support to European Space Agency

Retrieved on: 
Lunedì, Gennaio 31, 2022
Astronaut, Government, View, Natural gas, Rehabilitation, Intellectual property, EAC, Contract, ISS, Terrorism, European Astronaut Centre, SHINE, ESA, Radiation, Psychology, Engineering, European Space Agency, Technology, Dislocation, Research, COVID-19, NASA, Partnership, Health, KBR, Annual report, Risk, Compliance, Income, Tax, U.S. Securities and Exchange Commission, NYSE, Multimedia, Solution, Maintenance, Risk management

HOUSTON, Jan. 31, 2022 /PRNewswire/ --KBR (NYSE: KBR) was selected to continue providing high-endastronaut medical support services for the European Space Agency's (ESA's) European Astronaut Centre (EAC) Space Medicine Office in Cologne, Germany.

Key Points: 
  • HOUSTON, Jan. 31, 2022 /PRNewswire/ --KBR (NYSE: KBR) was selected to continue providing high-endastronaut medical support services for the European Space Agency's (ESA's) European Astronaut Centre (EAC) Space Medicine Office in Cologne, Germany.
  • Under the terms of the recompete contract, KBR will be the primary provider of space medicine support services to ESA, which is introducing a new service model.
  • "Every opportunity to work with ESA and our coordinating commercial and government space partners adds to the future of space exploration while highlighting its many positive beand globalizing our space expertise," said Byron Bright, KBR Government Solutions President.
  • KBR's partnership has also influenced millions in research funding for space medicine operations and led to the establishment of the ESA Space Health International Network for Exploration (SHINE).

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

Retrieved on: 
Lunedì, Gennaio 10, 2022
Trial of the century, AMD, Central nervous system, Cognition, U.S. Securities and Exchange Commission, CNS, Vance DeGeneres, Retina, Degenerative disease, The Michael J. Fox Foundation, Pathology, SHINE, Security (finance), Caggiano, Initial public offering, Muscle atrophy, CEO, Private Securities Litigation Reform Act, Biomarker, VP, Dementia, National Institute, SNAP, Next Generation, Therapy, ADAS, Hame, ACTC, IPO, SPARC, Patient, AD, Research, Risk, Nasdaq, COVID-19, DRS, GLOBE, Metabolism, National Institute on Aging, Disease, Conference, Absorption, CSF, DLB, Lewy body, Medical device, Pharmaceutical industry

In 2020, Cognition experienced a temporary delay in enrollment and patient treatment in the SHINE trial due to the COVID-19 pandemic.

Key Points: 
  • In 2020, Cognition experienced a temporary delay in enrollment and patient treatment in the SHINE trial due to the COVID-19 pandemic.
  • Management team: Anthony Caggiano, M.D., Ph.D., was appointed to the position of chief medical officer and head of R&D.
  • We expect to continue the momentum in 2022 to advance our ongoing and planned studies, bring forward new compounds to expand the pipeline.
  • Progress the Phase 2 Alzheimers Clinical Trials Consortium (ACTC) study with 540 early-stage AD patients, assessing cognition and biomarkers.

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Retrieved on: 
Martedì, Novembre 30, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, World Health Organization, Risk, Company, WHO, Pharmacokinetics, Nusinersen, Atrophy, SHINE, Orphan drug, Interim, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, CMO, Private Securities Litigation Reform Act, Security (finance), Motor neuron, FTD, World, Cancer, U.S. Securities and Exchange Commission, Patient, European Medicines Agency, Myostatin, Population, SMN, Clinical trial, Human, ODD, SAPPHIRE, Ageing, Therapy, Intellectual property, Survival, Investor, Muscle weakness, Fast Track, Neuromuscular Disorders, FDA, RPD, Gene, Growth, Pathology, X-linked spinal muscular atrophy type 2, Safety, SMN2, Program, COVID-19, Gongshi, Rock, SMN1, EMA, SMA, Fibrosis, Genetic disorder, NASDAQ, Pharmaceutical industry, Medicine, Health insurance, Surveying, Gemstone, Apitegromab, SMA, Scholar Rock, APITEGROMAB, SMA, SCHOLAR ROCK

We are excited to advance to the pivotal trial phase of apitegromab development through SAPPHIRE.

Key Points: 
  • We are excited to advance to the pivotal trial phase of apitegromab development through SAPPHIRE.
  • Patients receiving the background SMN treatment of nusinersen as well as patients receiving background SMN treatment of risdiplam will both be eligible for enrollment.
  • The SAPPHIRE design was informed by results from the TOPAZ phase 2 proof of concept trial of apitegromab in patients with Type 2 and Type 3 SMA.
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

Retrieved on: 
Giovedì, Ottobre 14, 2021
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, People, AASLD, HBV, Fibrosis, University of Washington, Respiratory disease, Disease, SERPINA1, University, 2021 Essex County Council election, Pizzicato, Medication, RNA interference, Blood, Tissue, RNA, Health, Patient, Neurodegeneration, Company, Hepatitis B, Association, Hepatocyte, Internet, Liver injury, Hepatitis B virus, Form 10-Q, Technology, Liver, RNA transfection, American Association, Roche, JK, SEC, Hepatitis, Therapy, DNA, Form, PMID, SHINE, The Lancet, Plasma, Eli Lilly, Hepatitis B Foundation, Nasdaq, Institute of Liver and Biliary Sciences, Cirrhosis, GeneReviews, Pain, Hepatocellular carcinoma, Degenerative disease, AAT, American Association for the Study of Liver Diseases, Novo Nordisk, Form 10-K, Hepatology, Pharmaceutical industry, Dietary supplement, Vaccine, Alpha-1 Antitrypsin (AAT) Deficiency and Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD), Belcesiran, Chronic Hepatitis B Virus (HBV) Infection, RG6346, Dicerna Pharmaceuticals, Inc., ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY AND ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE (AATLD), BELCESIRAN, CHRONIC HEPATITIS B VIRUS (HBV) INFECTION, RG6346, DICERNA PHARMACEUTICALS, INC.

Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.

Key Points: 
  • Both posters will be available for the duration of the meeting beginning on Friday, Nov. 12.
  • An estimated 10% or more of adults with AAT deficiency develop clinically meaningful liver disease.2,3 People with AAT deficiency may also develop lung disease, including emphysema.
  • Dicerna is currently investigating the use of belcesiran for the treatment of AATLD in the SHINE clinical development program.
  • The Liver Meeting is a registered trademark of the American Association for the Study of Liver Diseases.

Youth Leaders from United Nations and Global Citizenship Foundation Lead the Post COVID-19 Transformation on Planet Classroom

Retrieved on: 
Lunedì, Ottobre 11, 2021
UN, Program, Human, Education, Curriculum, UN Youth New Zealand, Association, Knowledge, Courage, Awareness, Solution, SHINE, SDG, Rock Your World, Organization, Tourism

The 4th industrial revolution created inequality, social discord, a fragile labor market and the need for innovation and change.

Key Points: 
  • The 4th industrial revolution created inequality, social discord, a fragile labor market and the need for innovation and change.
  • How can we reform curriculum to support the local good and the global good for all people?
  • Content showcased for youth and by youth on the Planet Classroom Network is provided by 29 cultural organizations from around the world.
  • Rock Your World, a program of Creative Visions, empowers educators and youth by facilitating multimedia advocacy.

SHINE’s new name highlights technology competencies and multiple phase opportunities

Retrieved on: 
Mercoledì, Settembre 22, 2021
Alternative Energy, Energy, Manufacturing, Technology, Radiology, Nuclear, Oncology, General Health, Medical Devices, Other Technology, Cardiology, Other Energy, Health, Utilities, Engineering, Carbon, Cancer, Degenerative disease, II, III, Half-life, SHINE, Multimedia, Patient, Â, Health technology, CEO, Isotope, Technology, Safety, Lithium, Renewable energy, Medical imaging

2021 (Photo: SHINE Technologies)

Key Points: 
  • 2021 (Photo: SHINE Technologies)
    SHINEs new name highlights the companys core technological competencies, skilled team and focus as a next-generation nuclear technology company.
  • SHINEs technology is currently being applied to advanced industrial inspection services and medical isotope production, phases I and II of the companys four-phase approach, respectively.
  • Phoenix commercialized phase I, advanced industrial inspection services, over a decade ago by utilizing its fusion-based technology for nondestructive testing.
  • SHINEs next step will be to explore the use of its technology to recycle nuclear waste in phase III.

Ribbon Cutting Ceremony Celebrates Opening of First Citrus Bank in the Heart of Downtown St. Petersburg

Retrieved on: 
Martedì, Settembre 21, 2021
Humanity, Taste, Chamber of commerce, SBA, Florida Community Bank, Community, SHINE, Loan, Arts centre, Heart, Nation, National Small Business Week, Central Avenue, Vitale, Growth, Commerce, Morean Arts Center, Â, Hyppo and Thomas, American Banker, GLOBE, Bank

Throughout the year, First Citrus Bank will continue teaming up with establishments throughout downtown to offer residents and employees of local businesses treats, tastings, and special offerings.

Key Points: 
  • Throughout the year, First Citrus Bank will continue teaming up with establishments throughout downtown to offer residents and employees of local businesses treats, tastings, and special offerings.
  • First Citrus Bank is true community bank that connects and enhances vibrancy throughout the community.
  • Sign up to receive updates from our new downtown location: bit.ly/FCBSTPETE
    First Citrus Bank, a $600 million commercial bank, was established in 1999 and is headquartered in Tampa.
  • First Citrus Bank enhances vibrancy throughout Tampa Bay by helping families become more financially secure and businesses economically successful.

Peak Fintech Acquires Heartbeat Insurance Platform and Brings Analytics and AI Expertise to Insurance Industry

Retrieved on: 
Martedì, Settembre 14, 2021
People, Software as a service, Artificial intelligence, PKK, Publication, AI, CBIRC, TNT, Ecosystem, Insurance, Company, Software, Risk, USD, Bank, Industry, CSE, NASDAQ, Shanghai Daily, Solution, CAD, Growth, Collection, Heartbeat, China Banking and Insurance Regulatory Commission, Hub, Acquisition, SHINE

Huayan provides its solutions primarily through its proprietary "Heartbeat" ( https://www.happysalers.com ) insurance product management and brokerage platform, where users pay a subscription fee to access the services plus a commission-related service fee when applicable.

Key Points: 
  • Huayan provides its solutions primarily through its proprietary "Heartbeat" ( https://www.happysalers.com ) insurance product management and brokerage platform, where users pay a subscription fee to access the services plus a commission-related service fee when applicable.
  • By gaining entry to the insurance industry through the acquisition of the Heartbeat platform and integrating it to the Business Hub, Peak believes it's in better position than ever to continue to influence various aspects of B2B transactions in China.
  • Heartbeat is currently linked to China's top insurance companies, including Ping An Insurance (Group) Ltd. , China Life Property & Casualty Insurance Company Ltd. , The People's Insurance Company (Group) of China Ltd. , and Bank of China Insurance Company Ltd .
  • About Peak Fintech Group Inc.:
    Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating primarily in the commercial lending industry.